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Table 1. Demographic and transplant details
No./Sex/Age (y) Diagnosis/Co-morbidities HLA match
TNC  107/kg
(cryopreserved)
Days to
ANC>500
Whole blood
chimerism/day post-tx Event Follow-up
1/M/2.03 MPS II / Cardiomyopathy 4/6 9.64 19 >98%/+623 A/W 655+
2/M/3.35 MPS IIIB 6/6 6.09 15 92%/+384 A/W 433+
3/F/3.32 MPS IIIB 5/6 6.08 28 63%/+112 Death 170
4/M/1.3 CHH 6/6 17.68 NE 0/+30 Graft failure 368+
5/M/6.76 MLD 5/6 5.88 24 >98%/+268 A/W 280+
6/F/3.32 Zap 70 def./Enteroviral meningitis, Resp.
MAI, Pseudomonas, Candida, Paraflu
5/6 8.3 21 >98%/+97 A/W 131+
7/F/0.45 HLH 5/6 22.27 19 >98%/+61 A/W 111+
8/F/0.58 HLH/Adenoviremia 4/6 14.19 20 >98%/+57 A/W 76+
Median: Age 2.67 8.97 20 280
MPS 5 mucopolysaccharidosis; CHH5Cartilage Hair Hypoplasia; MLD5Metachromatic Leukodystrophy; HLH5Hemophagocytic Lymphohistiocyto-
sis; NE5not evaluable; A/W5alive and well
S266 Poster Session Imelphalan (MEL) 140 mg/m2 and thiotepa (TT) 200mg/m2.
GVHD prophylaxis consisted of tacrolimus and MMF. All patients
received single UCBT; median age and weight at the time of trans-
plant were 3.3yrs and 15.1kg respectively; cryopreserved median cell
dose was 8.97x107 TNC/kg (range 5.9–22.3). HLA match was 4/6,
5/6 and 6/6 in 2, 4 and 2 patients respectively. Preparative regimen
was well tolerated. Maximummucositis was grade 3. To date, no pa-
tient has experienced CNS, cardiac, pulmonary or hepatorenal tox-
icity attributable to conditioning. Patient with Cartilage Hair
Hypoplasia (CHH) with no post-thaw CFU growth had autologous
recovery on day +30. He was successfully retransplanted with RIC
conditioning. The remaining patients (7 of 8) engrafted at a median
of 20 days post-transplant. At the last evaluation, whole blood donor
chimerism in engrafted patients ranged from 63% to . 98% with 6
of 7 engrafted patients. 90% donor. None of the patients have had
Grade 3-4 acute GVHD or extensive chronic GVHD thus far, al-
though follow-up for chronic GVHD is short. Untransfused platelet
count. 50K was achieved in all engrafted patients at a median of 39
days. Viral reactivation and/or de novo viral infections were seen
commonly but without appreciable end organ disease. Adenovirus
infection was noted in 5 patients (1 patient had adenoviremia that re-
solved with cidofovir and adoptive immunotherapy); the patient with
autologous recovery had prolonged CMV viremia. Seven of 8 pa-
tients are alive with a median follow-up of 280 days. One patient
with mixed chimerism died on day +170 of an acute hemolytic trans-
fusion reaction. The first two patients are off immunosuppression
with age appropriate immune profiles.
Conclusions: RIC with alemtuzumab, HU, FLU, MEL, TT is well
tolerated and results in a high rate of donor engraftment with a low
risk of GVHD and regimen related toxicity in children with chemo-
therapy na€ıve non-malignant diseases undergoing UCBT.308
IMPACT OF A PRUDENTQ CONSERVATIVE RED BLOOD CELL TRANSFU-
SION STRATEGY IN CHILDREN UNDERGOING HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Lightdale, J.R.1, Tran, C.M.2, Randolph, A.G.1, Jiang, H.1, Colon, A.2,
Houlahan, K.E.3, Sloan, S.1, Lehmann, L.E.3 1Children’s Hospital Bos-
ton, Boston, MA; 2The Physician’s Organization at Children’s Hospital
Boston, Boston, MA; 3Dana Farber Cancer Institute, Boston, MA
Prior to 2009, stable patients in our hematopoietic stem cell trans-
plant (HSCT) unit received routine transfusions for hemoglobin\9
g/dL. In February 2009, we changed this transfusion threshold to
Hgb\7 g/dL based on published data in critically ill but stable pe-
diatric intensive care unit patients. AIM: The aim of our study was to
assess the impact of changing to a conservative transfusion strategy in
children undergoing HSCT at our institution.
Methods:We compared census and transfusion data obtained dur-
ing primary admissions for HSCT using the prior transfusion
threshold (1/1/08-12/31/08) and after implementation of the conser-
vative transfusion threshold (3/1/09-2/28/10). All transfusion deci-
sions in both study periods were made at the discretion of
physician attendings. Data was analyzed with help from the PRU-
DENT quality improvement team, which focuses on PediatricResource Use and the Determination of Effective and Necessary
Targets at our hospital.
Results: 66 patients admitted for HSCT pre-intervention were
compared with 75 post-intervention. Pre-and post- patients were
of similar ages (median 6 (IQR 2, 12.5) vs. 6 (3, 13) yrs old, p 5
.8), and underwent similar types of transplant (22 (33%) vs. 26
(35%) autologous, p 5 .9), for similar diagnoses. Similar numbers
of patients received at least one transfusion in the two periods (65
(98.5%) vs. 72 (96%), p 5 .4). Post-intervention patients, however,
received significantly fewer RBC units (median 4 (IQR 3, 8) vs. 3
(2,5), p 5 .002) and had fewer transfusion days (median 4 (IQR
2, 5) vs. 3 (2, 5), p 5 .01). In addition, median Hgb pre-transfusion
significantly decreased from 8.8 g/dL to 6.8 g/dL (p \ .0001).
Patient outcomes appeared similar, with no differences in median
length of stay in days (37 (IQR 30, 46) vs. 37 (29, 52), p 5 .7),
median days to engraftment (20 (IQR 12, 25) vs. 18 (12, 24),
p 5 .7) or 100 Day Mortality (26% vs. 18%, p 5 .2). Finally,
median blood product related charges were significantly less
post-intervention ($3624 (IQR $2265, $6040) vs. $2185 ($1812,
$3997), p 5 .004).
Discussion: A review of our institutional experience suggests a con-
servative transfusion target of a Hgb of\7 g/dL in otherwise stable
children undergoing HSCT results in fewer transfusions without in-
creasing adverse outcomes. Further study is required to fully evaluate
the safety of this practice as well as to comprehensively assess its im-
pact on the provision of high-value, high-quality care in pediatric
HSCT units.309
CLONAL EVOLUTION IS A STRONGER PREDICTOR THAN DISEASE STATUS
OF DISEASE-FREE SURVIVAL AFTER PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Hudspeth, M.P., Chiuzan, C., Garrett-Mayer, E., Nista, E.,
Robertson, J., Wolff, D.Medical University of South Carolina, Charleston,
SC
Background: Clonal evolution as a model of tumor development
and progressionwas first proposed byNowell in 1976.Genetic insta-
bility of tumor cells leads to subpopulations with additional cytoge-
netic abnormalities. Subpopulations with cytogenetic abnormalities
that confer a survival advantage become the dominant population
leading to progression. Although clonal evolution has been generally
viewed as an adverse event, there is limited data regarding the effect
on outcome after HSCT.
Methods: We conducted a retrospective chart review of pediatric
patients who underwent HSCT for leukemia beyond CR1/CP1 or
with refractory disease from 2005-2010. Three patients with isolated
CNS relapse and two patients with JMML were excluded. Cytoge-
netic analyses from diagnosis and relapse were compared for 16 pa-
tients. Ten of these patients had clonal evolution, defined as an
additional cytogenetic abnormality from diagnosis. Relapse-free sur-
vival was analyzed using the Kaplan-Meier method and the differ-
ences between survival curves were tested using a log rank test at
a 0.05 significance level.
Poster Session I S267Results: Disease status (relapse/refractory, CR2, or CR3) did not
have a significant effect on disease-free survival (p 5 0.75). Clonal
evolution, however, did have a significant negative impact on dis-
ease-free survival (p 5 0.03). Day 100 disease free survival was
50% versus 100% for patients with and without clonal evolution, re-
spectively. Similarly, one year disease-free survival was 20% and
83% for patients with and without clonal evolution. Among the pa-
tients with clonal evolution, there was no significant difference in
disease-free survival between patients with only one new cytogenetic
abnormality and those with more than one new cytogenetic abnor-
mality (p 5 0.19).
Conclusion: Clonal evolution appears to identify a very high-risk
group of patients who may benefit from novel transplant strategies
and post-HSCT interventions. Future studies should seek to validate
these findings in a multi-institutional setting.310
HYPERTENSION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS
Owens, C.1, Ashraf, K.1, Chong, D.1, Stesco, N.1, Depuis, L.1,
Fernandez, C.2, Gassas, A.1, Nathan, P.1, Doyle, J.1, Schechter-
Finkelstein, T.1 1Hospital for Sick Children, Toronto, ON, Canada;
2 IWK Health Center, Halifax, NS, Canada
Allogeneic haematopoietic stem cell transplant (AlloHSCT) in
children is associated with serious complications. Hypertension
(HT) is reported to occur in 21-63% of adult HSCT patients.
Data on the incidence of HT in children undergoing HSCT are lim-
ited.
Objectives: To establish the incidence of and identify the risk fac-
tors associated with the development of HT in pediatric AlloHSCT
patients and to determine the duration and impact of HT on cardiac
function at one year and overall survival (OS).
Methods: We conducted a retrospective study of all children who
underwent AlloHSCT at The Hospital for Sick Children from
2004 to 2007 and were followed in Toronto or Halifax. Demo-
graphic information, underlying diagnosis, conditioning regimen,
GvHD prophylaxis, blood pressure, GvHD, survival, medication
history and echocardiography results were collected in the first
year post HSCT.
Results: 172 children (59% male; mean age 5 8.46 years; range
0.25-18 years) underwent AlloHSCT during the study period.
67% had an underlying malignant disease; 83% received myeloabla-
tive conditioning and 45% received total body irradiation. 93% re-
ceived cyclosporine for GVHD prophylaxis, most commonly in
combination with methotrexate (78%). Stem cell donors were: living
related donor (LRD) in 51%; living unrelated donor (LURD) in
33% and unrelated cord in 16%.
111/172 (65%) developed HT in the first 100 days after Al-
loHSCT.Childrenwithmalignant disease were less likely to develop
HT compared to children without a malignancy (p\ 0.008). Chil-
dren who had a non-cord HSCT and developed GVHD were
more likely to develop HT (p 5 0.045). Gender, age and condition-
ing regimen were not associated with HT. 36/149 (24%) evaluable
children were hypertensive at D+90, 16/138 (12%) at D+180 and
5/126 (4%) at one year. No child had ventricular dysfunction (mea-
sured by echo) at one year. A total of 46 patients had died by one year
post transplant. HT did not influence OS at one year after Al-
loHSCT (p 5 0.37).
Conclusions:HToccurs commonly post AlloHSCT in children but
usually resolves by one year post transplant. HT did not lead to car-
diac impairment or influence OS at one year.311
SIGNATURE PROFILES OF CMV-SPECIFIC T-CELLS IN PEDIATRIC PA-
TIENTS WITH CMV REACTIVATION AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Krol, L.1,2, Stuchly, J.2, Hubacek, P.1, Sedlacek, P.1, Kalina, T.1,2
1Charles University 2nd Faculty of Medicine and University Hospital Mo-
tol, Prague, Czech Republic; 2Charles University 2nd Faculty of Medicine
and University Hospital Motol, Prague, Czech RepublicDepletion of cellular immunity as a consequence of condition-
ing before allogeneic hematopoietic stem cell transplantation fre-
quently results in CMV reactivation, which may in turn lead to
life-threatening infections and require timely antiviral treatment.
We have investigated the functional signatures of CMV-specific
CD4+ and CD8+ T-cells in 191 samples from 118 individuals.
We included patients with either high or undetectable viral loads,
and those who controlled or did not control their CMV reactiva-
tions. All patient subsets were compared to healthy donors. Poly-
chromatic flow cytometric measurements of CD154 (CD40L),
intracellular cytokines (IFNg, IL2), and a degranulation marker
(CD107a) revealed the functional status of various T-cells simul-
taneously. We found that dual IFNg/IL2 producing CD8+
T-cells were significantly decreased in patients non-controlling
their CMV reactivations compared to controllers. In contrast,
CD8+ T-cells that produced IFNg only were the most abundant
subtype but they were present in a substantial number of non-
controllers. Hierarchical clustering of distinct functional signa-
tures revealed that polyfunctional CD8+ T-cells were acting in
concert with other subsets, whereas the isolated production of
IFNg by CD8+ T cells heralds insufficient collaboration with
others. In conclusion, our study revealed functional signatures
that may be useful for immune monitoring, and they may change
the interpretation of previous studies that assessed only IFNg.
Supported by the Czech Ministry of Health grant NS/9996-4 and
VZ0FNM2005.312
MOLECULAR DETECTION OF ADENOVIRUS IN PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT RECIPIENTS
Watson, T.M.1, MacDonald, D.2, Song, X.3,2, Bromfield, K.1,
Stevenson, A.1, Campos, J.M.2,3, Sande, J.1,3, DeBiasi, R.L.3,2 1Child-
ren’s National Medical Center, Washington, DC; 2Children’s National
Medical Center,Washington, DC; 3GeorgeWashingtonUniversity School
of Medicine, Washington, DC
Background: Adenoviral (AdV) infections are a major cause of mor-
bidity and mortality in hematopoietic stem cell transplant (HSCT)
patients (pts). Quantitative molecular detection of AdV using poly-
merase chain reaction (PCR) has recently becomemore widely avail-
able in the clinical setting for early detection and monitoring of AdV
infection, although challenges regarding interpretation of results and
implications for treatment remain.
Methods:Weperformed a retrospective cohort study of all pediatric
HSCT pts who underwent AdV PCR testing from May 2008
through April 2010. Clinical characteristics of AdV-positive (POS)
pts were compared to AdV-negative (NEG) pts.
Results: Of 48 pts with AdV testing, 43 had complete transplant
records and were included in the analysis. Seven (16.3%) pts were
AdV-POS. Overall pt characteristics were comparable between
the two groups. The following medication exposures were identi-
fied as risk factors influencing AdV status: preparatory regimens
utilizing fludarabine (Relative Risk [RR] 8.73, 95% Confidence
Interval [CI]: 1.18-64.27, p 0.006), melphelan (RR 3.47, 95%
CI 0.76-15.94, p 0.08), and/or cyclophosphamide (RR 0.18,
95% CI 0.02-1.4, p 0.05), and GVHD prophylaxis with methyl-
prednisone (RR 3.73, 95% CI 1.01-13.9, p 0.04). AdV-POS pts
had higher GVHD grades with higher rates of GVHD of the gas-
trointestinal tract (RR 4, 95% CI 1.18-13.5, p 0.03) compared to
AdV-NEG pts. Amongst seven AdV-POS pts, 57.1% had con-
comitant clinical manifestations of disease including: pneumonia,
diarrhea, and/or disseminated disease. Clinical outcomes in four
symptomatic pts included resolution of disease (2) and death (2),
although one pt had concomitant bacterial sepsis. An additional
AdV–POS pt had prolonged marrow suppression as a probable
clinical manifestation of AdV disease and recovered. All AdV-
POS pts received antiviral therapy, including one pt with severe
disseminated disease that resolved following administration of li-
posomal cidofovir.
Conclusion:Our study at a large pediatric HSCT transplant cen-
ter confirms previously identified risk factors for AdV infection in
previous small studies in adults and children. This study provides
important preliminary data for the design of a prospective trial
which aims to identify specific HCST patient populations who
